ActaBiomedicaScientia

e - ISSN - 2348 - 2168
Print ISSN - 2348 - 215X

www.mcmed.us/journal/abs

Research Article

SNAP (S-NITROSO-N-ACETYL PENICILLAMINE) HAS LONG-TERM BIOCOMPATIBILITY THROUGH COVALENT IMMOBILIZATION AND EXHIBITS SUSTAINED NITRIC OXIDE RELEASE FOR 4 MONTHS

Dr. Parija Jyothi Prakash*

Associate Professor, RVS Institute of Medical Science, Chittoor, Andhra Pradesh, India.

ABSTRACT

Over the past three decades, researchers have developed a variety of NO-releasing polymeric materials after discovering the importance of endogenous nitric oxide in regulating a wide range of biological processes. Almost all of these materials have short lifespans because NO donor molecules are poorly incorporated into the polymer matrix. To develop a stable material that releases nitric oxide (NO), S-nitroso-N-acetylpenicillamine (SNAP) was combined with polydimethylsiloxane (PDMS). No NO donor can be leached into the environment because SNAP is anchored to the PDMS crosslinker. It has been the first time that a NO-releasing polymer has been able to continue releasing NO and suppressing bacteria over this period, indicating that it may have long-term hemocompatibility and biocompatibility. By demonstrating a 99.99 percent reduction in a continuous flow CDC bioreactor after three days and a 99.50 percent inhibitory potential after a month, the material shows excellent antibacterial activity against Staphylococcus aureus. A rabbit extracorporeal circuit (ECC) model was used to test SNAP-hemocompatibility PDMS's during a 4-hour period. When compared to the control circuits, thrombus growth was dramatically reduced in the SNAP-PDMS coated ECCs, The overall thrombus mass was reduced by 78 percent. This material may prove useful for long-term clinical applications for biomedical devices in contact with blood and tissues when infection and unwanted clotting are significant concerns.

Keywords :-S-nitroso-N-acetyl penicillamine, Intercorporeal circulation, bioreactor, antimicrobial, biocompatible.

Access this article online		
Home Page: www.mcmed.us/journal/abs		**Quick Response code**
Received:25.06.2019	**Revised**:10.07.2019	**Accepted**:28.07.2019

INTRODUCTION

When foreign objects or medical equipment make contact with blood, proteins such as albumin and fibrinogen adhere to its surface, making it easier for platelets to adhere. In platelets that have been attached to proteins, the glycoprotein GPIIb/IIIa receptor is exposed, allowing platelets to bind to fibrinogen directly. Platelets are activated and aggregated, which results in clotting. As a result, these clots can break off and cause emboli lower down in the vasculature, as well as reduce the effectiveness of the implant. A clinical setting may also present the risk of infection with medical equipment. Catheters and endotracheal tubes may become infected if they are kept in place for too long. The devices must be removed and replaced frequently, requiring extensive surgeries and causing pain to the patients.

The use of nitric oxide as a biocompatibility promoter is possible in specific circumstances (NO) (NO). Biological signals are produced by nitric oxide, afree radical. Physiological functions includeeliminating pathogens via nitrosative stress,preventing

Corresponding Author**: Dr. Parija Jyothi Prakash** Email: **drvrvkk@gmail.com**

platelets from adhering to the vasculature, and regulating blood pressure via vasodilation. In certain conditions, certain NO-releasing drugs can mimic important endogenous functions by understanding these pathways. A form of NO-releasing chemicals known as S-nitrosothiols (RSNO) is produced in the body. S-nitroso-N-acetyl penicillamine (SNAP), S-nitrosoglutathione (GSNO), and S-nitrosocysteine are some examples of RSNOs that are combined into polymeric matrices to promote localized and controlled NO release. RSNOs produce NO through the breakdown of the sulfur-nitrogen bond. This breakdown is aided by temperature degradation, metal ion catalysis, and/or light. As RSNO-containing materials can slowly release NO under in vivo conditions, thermal degradation is one of the most widely used methods for initiating the release. A third kind of NO donor is a dizeniumdiolate, which releases a huge amount of NO over a short period of time when the physiological temperature and pH are right. [8]

The effect of NO releasing polymers on thrombus prevention in vivo has been fully explored in both extracorporeal circuit (ECC) and catheter studies.

Due to the short half-life of NO, its way of reducing platelet activation is more localized than that of other reducing agents. People with low platelet counts, internal bleeding, and thrombocytopenia may experience side effects of heparin and other blood thinners. Thrombus formation and platelet adhesion are significantly reduced by polymers that create NO, as they inhibit both ECC and catheter surface adhesion without detrimental systemic consequences.

A medical device that contacts tissue also poses a risk of infection. There have been many attempts to create antimicrobial surfaces using nanoparticles and polymers that facilitate the diffusion of antibiotics such as silver17–19 and copper20–22. These metallic nanoparticles, if used in high concentrations, may be toxic to both the tissue surrounding them and the germs they are targeting. The rise in antibiotic resistance has also resulted in a reduction in medication effectiveness. Biofilms, which cover bacteria with proteins and polysaccharides, have also been shown ineffective against antibiotics. By using this method, NO is prevented from leaching outside of the polymer matrix, which would normally result in bursts of NO within a short period of time and depletion of the NO reservoir. A substantial, regulated release of NO has also been demonstrated using high molecular weight, covalently bound NO donors, such as RSNOs and diazeniumdiolates. A long-term delivery of NO to cells using these synthetics has shown potential in vitro to be stable. [38–39]

We examined whether SNAP-PDMS could be used as an antibacterial agent long-term and to prevent unwanted thrombus formation. SNAP was shown to possess lifetime release capabilities in vitro by By releasing NO over time, the silicone rubber can support the production and adaptation of a range of biomedical devices, including blood and urine catheters, PICC lines, and feeding tubes. A rabbit model was used to observe thrombus formation and platelet count using 4-hour ECC tests using SNAP-PDMS on the inner lumen of PDMS tubing. A separate experiment examined the antibacterial properties of SNAP-PDMS films in a CDC biofilm reactor for 28 days.

Procedures and Materials

Materials:

This work was conducted at Sigma-Aldrich using N-Acetyl-D-penicillamine (NAP), polydimethylsiloxane-dibutyltrimethoxysililane, toluene, chloroform, pyridine, tributyl nitrite, acetic anhydride, poly(dimethylsiloxane) 2550–3570 cSt (PDMS), and ethylenediaminetGibco-Life Technologies donated the antibiotic Penicillin-Streptomycin (Pen-Strep) and fetal bovine serum (FBS) (Grand Island, NY) (Grand Island, NY). The American Type Culture Collection donated the bacterial strain Staphylococcus aureus (ATCC 5538) and mouse 3T3 cells (ATCC 1658). (ATCC 1658).

NAP-thiolactone synthesis

The proven procedure developed by Moynihan and Robert was used to synthesize thiolactone self-protected NAP.

40 In a round bottom flask, 5 g of NAP was dissolved in 10 mL pyridine, while a separate vial containing 10 mL pyridine and 10 mL acetic anhydride was made. Both solutions were refrigerated for 1 hour in an ice bath before being blended and swirled for 24 hours. A rotary evaporator was used at 60°C to evaporate the solution until all of the pyridine was gone and a thin, orange solution was all that remained. To extract 1M HCl three times from the rest of the solution in equal volume amounts, it was diluted with 20 mL chloroform. Drying the organic layer and then filtering it over anhydrous magnesium sulfate were the next steps. The solid is washed and filtered with hexanes after being extracted with chloroform under vacuum at room temperature. It is collected at room temperature over night and dried for two days before being stored at 5°C (1.16 g).

SNAP-PDMS synthesis

Frost et alprocedure .'s was slightly changed to make SNAP-PDMS

To isolate the hydroxy terminated PDMS, 1.6 g were dissolved in 8 mL of toluene in the first step, as shown in the schematic. Three grams (3,4-diaminopropyl) trimethoxysilane (1,67 mmol) and two grams dibutyltindilaurate were dissolved in two milliliters of toluene in another vessel. After that, the two

solutions were united and properly mixed before being agitated overnight. In the crosslinked PDMS solution, a tiny amount of NAP-thiolactone (300 mg, 1.73 mmol) was mixed in excess of the crosslinking agent and agitated for 24 hours. Addition of t-butyl nitrite nitrosated the NAP-PDMS. After vortexing three times with a 20 mMcyclam solution to remove copper impurities, the t-butyl nitrite was chelated again to remove remaining copper. After separation, the organic t-butyl nitrite layer is stored in an amber vial at 5 °C. 300 mL of t-butyl nitrite plus 3 mL of NAP-PDMS is used to create a deep green SNAP-PDMS solution. The nitrosated solution was then placed in a Teflon ring with a diameter of 2.54 cm, sealed against light, and allowed to air dry overnight.

Assay for SNAP leaching

A Thermo Fisher Genesys 10S UV-Vis spectrophotometer was used to investigate leaching of SNAP-PDMS bound to and blended together. Since S-nitroso bonds dominate RSNOs, their maximum absorbance is observed at 340 and 590 nm. To be sure that the buffer was free of catalytic metal-ion interactions, coated SNAP-PDMS and SNAP-PDMS blend films were soaked in PBS (0.01M) with 100 m EDTA for varying amounts of time. The covalently bound SNAP-PDMS as well as blended SNAP in PDMS were evaluated with and without a PDMS topcoat. The film was incubated in PBS with EDTA and sheltered from light during the trial in order to preserve the SNAP leaching values. PBS solution aliquots were measured at 340 nm after being placed in cuvettes.

Bacterial adhesion assay

SNAP-PDMS was tested against Staphylococcus aureus in a continuous flow CDC bioreactor (BioSurface Technologies) for 3, 14, and 28 days to determine its ability to reduce bacterial adhesion and growth. The formation of biofilms on polymeric surfaces can be facilitated by providing nutrients in a steady supply, the use of a CDC bioreactor offers a highly favorable environment for bacterial growth, which can be utilized to assess the polymer's long-term performance. From a pregrown culture, a single isolated colony of the bacterial strain (S. aureus) was incubated overnight in LB medium at 150 rpm at 37 °C. Using a UV-vis spectrophotometer, the optical density OD600 measurements of the liquid suspension of bacteria were made after 14 hours, which confirmed previous observations. In addition to being sterilized for 30 minutes in a BioSafety Cabinet (Thermo Scientific 1300 A2) before being placed in the CDC bioreactor for analysis, the samples (SNAP-PDMS and control PDMS, n=3 for each time point) were then added to the CDC bioreactor for analysis. CDC bioreactors are sanitized according to the manufacturers' instructions in an autoclave with saturated steam at 121 °C for 30 minutes before use. As a trend analysis, the final OD600 for the CDC bioreactor (working volume 1000 mL) fell in the range of 107–109 CFU mL1 when it was infected with the bacterial culture in 400 mL of LB medium (2 g L1). A sterile feed bottle fed LB medium (2 g L1) to the CDC bioreactor on one end, and the wash out came from a sterile collection bottle on the other end. We rinsed the films (controls and tests) three times with PBS every three, fourteen, and 28 days to remove loosely bound bacteria. We homogenized the washed films for 60 seconds in sterile PBS and 15 mL tubes using an OmniTip homogenizer. After that, using an L-spreader, bacterial strains were plated on numerous Petri-dishes on LB-agar medium and serial dilutions (101 to 105) were made using sterile PBS.

In vitro cytotoxicity of cells

Using 3T3 murine fibroblast cells, the ISO 10993 standard was employed to investigate cell cytotoxicity on SNAP-PDMS films (ATCC-1658). The Cell Counting Kit-8 (CCK-8) technique used the WST-8 dye, an inorganic compound that contains 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt. Formazan is detected at 450 nm when WST-8 is reduced enzymatically, which in turn generates formazan. In that case, cell death is not necessary for the determination of the number of living cells.

The mouse fibroblasts were cultured in 75 cm2 T-flasks containing DMEM containing 4.5 g glucose and L-glutamine, 10% FBS, and 1% penicillin-streptomycin with 5% carbon dioxide at 37 °C. Confluence approaching 90% was tested by trypsinizing (0.18 percent trypsin and 5 mM EDTA) and planting cells in 96-well plates at a density of 5000 cells per well. By incubating the PDMS and SNAP-PDMS films for 24 hours at 37 °C, leachates were made from control PDMS and SNAP-PDMS films simultaneously. Cell culture experiments were conducted at 4 °C using DMEM extracts after the films had been removed from the solution and discarded.

To study cytotoxicity, 5000 cells mL1 of the previously generated suspension were placed into 96 well plates (100 L in each well). After 24 hours of incubation with 5% CO2, the 96-well plate was added to 10 L of leachates. A subsequent 24 hour incubation was conducted to allow the leachates to affect the cells. After that, each well received 10 mL of CCK-8 solution, which was incubated for another 3 hours. The relative cell viability was estimated by comparing the cells with and without leachate using a 450 nm absorbance measurement. The percentage of cell viability was calculated using the calculation below.

RelativeCellViability = Absorbance of test samples (percent) The absorbance of the control samples was 100.

Extracorporeal circuits are being prepared

The ECC loop arrangement was used, as previously described

A thrombogenicity chamber was created using a 16-gauge IV polyurethane angiocatheter and a 14-gauge IV polyurethane angiocatheter. The angiocatheters were coated only once with an 80 mg/mL more diluted SNAP-PDMS solution. PDMS 80 mg/mL1 in toluene was used to construct all of the ECC loops. NO loss from the tube and coating solutions was minimized by preventing direct sunlight exposure during the procedure. Before being vacuum dried for 24 hours, the ECC loops were room temperature dried for 48 hours. During the rabbit experiment, ECC loops were soaked for one hour in a saline solution. We measured NO release by using small tubing lengths before and after the trial.

Rabbit ECC Model

The SNAP-PDMS coated tubing's hemocompatibility was examined using a rabbit ECC model that has previously been used. It was used as a maintenance anesthetic in a 100 percent oxygen environment, administered by tracheotomy at a 1–3% breathing rate. Mechanical ventilation was used to maintain anesthesia with isoflurane in 100% oxygen (from 0.5–1.5%) at a rate of 12 breaths per minute and a tidal volume of 10–15 mL kg1 (Hallowell EMC, Pittsfield, MA 01201). To precisely monitor blood pressure, a Doppler ultrasonic flow probe was employed (Parks Medical, Las Vegas, NV 89119). The continuous ECG and heart rate were closely monitored using a multiparameter monitor (Grady Medical, Los Angeles, CA). Lactated Ringer's were supplied via catheterization of the ear vein at a rate of 10 mL kg1 h1 to help maintain blood pressure stability. Body temperature was measured using a rectal probe and maintained at 38 °C using a warm water heating blanket and a forced air heater. To obtain baseline measurements, blood samples were taken before the ECC trial began.

ECCs are cannulated into the right carotid artery and left jugular vein, primed with NaCl, clamped, and placed into position. The ultrasonic flow probe and the flow meter (Transonic 400 Ithaca, NY) showed that once the end of the ECC was unclamped, blood flowed freely through the loop. As soon as the flow rate decreased to 0 mL min-1 and remained there for 5 minutes, the ECC loop was judged closed. We collected, weighed, and preserved any ECC loop clots found. Animals were not given any systemic anticoagulants during the study.

Indirect catheterization of the femoral artery was used to collect blood samples for a complete blood count using an automated hematology analyzer (Heska Element HT5 Hematology Analyzer, including platelet count). Blood samples were collected every hour after the ECC had been turned on for four hours. The blood samples were each taken at 1 mL. Impedance counters (CBC-Diff, Heska Corp., Loveland, CO) were used to monitor the completion of the blood count.

Analytical statistics are a type of statistical analysis

The data's mean and standard deviation were determined. SAS JMP software and a student's t-test were used for statistical analysis. If the P value was less than 0.05, all of the data in the study was judged statistically significant.

The Results Are Discussed

Nitric Oxide Release Measurements and Characterization

A chemiluminescence nitric oxide analyser was used to measure the NO release from SNAP-PDMS films in real time. Analyses of samples were carried out with EDTA buffer and 0.01M PBS in amber reaction containers containing 0.01M PBS at 37 °C with nitrogen bubblers and sweep gas at a combined flow rate of 200 mL/min in amber reaction containers containing 0.01M PBS. The same SNAP-PDMS films were incubated for the same period of time under NO testing conditions. We found that tertiary RSNO modified films still had a green color after the experiment was completed, which indicated that NO was still being emitted. This section summarizes how the NO release kinetics of the films evolved throughout the study. In this example, the flux emitting from the films at various times is shown, and the PBS used to incubate them is regularly changed. Despite not yet exhausting themselves, the films yielded a NO flux of 0.1 1010 mol cm2 min1. A pattern of cumulative NO release has been shown in this graph through the course of the testing period, indicating not only the material's significant capacity to store NO, but also its initial release profile when introduced to PBS on day 0. SNAP load capacity was determined by UV-VIS testing, and the films weighed and measured prior to testing. After day 125, the total NO release was normalized to 0.311 0.009 mol mg1, showing that 18% of the covalently coupled SNAP remained. NO donor leaking from the polymer matrix is a common source of this. Leaching is an issue with non-covalently attached medications, hence a polymer topcoat is occasionally Preventive measures are used. In the case of compounds that require long-term release of NO, the method is less suitable.

The NO release from silicone rubber tubing with SNAP-PDMS coatings was mimicked during in vivo ECC experiments by testing them for 4 hours. The inner surface of the SR tubing was cast with three coats of SNAP-PDMS in toluene (160 mg mL1) after it was filled

and drained. Each coat was allowed to dry for one hour. SNAP-PDMS solution must be removed from the tube between each drying step. A smooth surface in the lumen of the tubing removes the unevenness of polymer layers, resulting in a uniform NO release throughout the whole circuit during testing. A 24-hour vacuum drying procedure was performed on the tube before any remaining solvent was evaporated during the ECC experiment. To determine that the release of nitric oxide matched the results of earlier in vitro testing, nitric oxide release was measured following in vivo ECC testing. The NO flux was 8.15 1.68 1010 mol cm2 min1, compared to 8.35 0.666 1010 mol cm2 min1 before testing.

Measurements of SNAP Leachates

When utilized in aquatic environments, SNAP-PDMS does not require a topcoat to prevent leaching, which reduces processing time and allows for the application of extremely thin polymer coatings to a surface. Silicone rubber-based polymer topcoats, on the other hand, can limit the diffusion of certain ions while reducing the amount of water absorbed by the films. This could extend its life even more by limiting NO release to heat exclusively, resulting in a lower overall NO flux. It's probable that the materials will take a long time to maintain a stable flow due to the continuous leaching of the NO donor. When comparing the burst release of SNAP-PDMS to that of these polymers, the SNAP-PDMS burst release is significantly shorter.

Covalently attaching SNAP to the PDMS instead of integrating it into the polymer greatly reduces the amount of leaching. As a prophylactic measure, hydrophobic topcoats were once preferred to keep SNAP mixed within polymer matrixes. Although SNAP leaching decreases significantly with this technique, it is still much higher as compared to covalently attached SNAP-PDMS.

At 340 nm, UV-Vis absorbance spectroscopy was used to measure the amount of leaching on the films. For the first 24 hours of testing, the same PBS solution was used, and then a new batch of PBS for the following 24 hours, allowing for a calculation of cumulative leaching. The SNAP-PDMS films showed modest leaching (0.015 mg cm1) after 48 hours of soaking in PBS at room temperature, however the blended SNAP films showed continual leaching. The amount of SNAP leached from blended films continues to climb, despite the adoption of a protective topcoat. As a result, after the first 6 hours of measurement, SNAP-PDMS film leachates remained relatively constant for the remainder of the study.

For a Long Time, Bacterial Inhibition on SNAP-PDMS

Because of the surface features of surgical implants and the failure to keep sterile conditions during procedures, they are vulnerable to infection. Because catheters are left in place for lengthy periods of time, they are prone to infection. The device's lifespan is shortened as a result of these infections, necessitating its replacement before it becomes life-threatening. As a result, biomedical device-related infections increase not only the patient's suffering, but also the overall cost of healthcare due to the increased length of stay in the hospital. To minimize medical issues like this, it's vital to have long-term antibacterial programs in place. The two key criteria that support bacterial adherence and growth are the material's surface roughness and the potency of the bactericidal agent emitted. Most tests measure the effects of nitric oxide-releasing compounds for only a few minutes, despite the fact that their ability to inhibit bacterial activity has been demonstrated. S. In a CDC bioreactor, aureus was incubated with SNAP-PDMS films 50–51, 44–48, 44–48, 44–48, 44–48, 44–48, 44–48 for 3 days, 14 days, and 28 days, as well as a separate experiment involving films that have continuously released NO for at least 125 days. One of the most common causes of hospital-acquired infection is Staphylococcus aureus. Antibiotics are rendered ineffective due to the formation of a biofilm on the polymeric surface.

Using a bioreactor, the films can be sheared and bacteria can be fed, simulating an in vivo highly favorable environment.

In bioreactors at the Centers for Disease Control and Prevention, 52 SNAP-PDMS films were placed with S. pneumoniae for 28 days. The bioreactors were maintained at 37 °C. We retrieved the films at the following time points: days 3, 14, and 28 (n=3). A sonicator (Omni International TH) was used to homogenize the films in sterile PBS solution after their removal from the bioreactors in order to remove loosely bound bacteria. The bacterial suspension was serially diluted in PBS (101 to 105) and then plated in pre-made LB agar plates (40 mg/ml) after serial dilutions (101 to 105) of the suspension. During all time intervals, the number of live S. aureus was significantly reduced on the SNAP-PDMS films. By day 14, the reduction had decreased by three logs, and by day 3 had reduced by four logs. At these dates, the SNAP-PDMS was emitting a considerable amount of NO. A two-log decrease in viable bacteria was still apparent in SNAP-PDMS films after 28 days, when NO release begins to decline. Throughout the bioreactor experiment, Table 1 shows the specific values.

TABLE 1: Counting colony forming units (CFU) at specified times before and after bioreactor study.

	Notion(initial) (x10*10 mol cm*2 sec*1)	**Flux(28d) (x10*10 moles cm2 sec1)**	**$CFU_{(3d)}$**	**$CFU_{(14d)}$**	**$CFU_{(28d)}$**
CFU(90d)	-	-	$3.04 \times 10^8 \pm 7.30 \times 10^7$	$1.71 \times 10^8 \pm 1.21 \times 10^6$	$2.04 \times 10^9 \pm 3.91 \times 10^8$
SNAP-PDMS	8.34 ± 0.665	1.01 ± 0.120	$2.10 \times 10^4 \pm 5.08 \times 10^3$	$8.37\times 10^4 \pm 3.02 \times 10^4$	$1.03 \times 10^7 \pm 3.04 \times 10^6$

To conclude, residual NO flux was measured after the bioreactor research to get an idea of how successful the films would be after 28 days of testing. It was shown that SNAP-PDMS films can still be used as antibacterial filters even after 28 days of bacteria death, by emitting a flux of NO of 1,01 0,120 1010 mol min 1 cm2. NoNO is being emitted at this rate that is higher than the amount determined in vitro for the films in PBS after 28 days, which only showed a flux of 0.5 1010 mol min1 cm2. The differences between preserving films in a bioreactor versus keeping them in PBS can be attributed to some factors that are different when the films are preserved in a bioreactor. A biological "topcoat" can build up on the surface of polymer films, preventing NO from leaving the film as quickly as it would otherwise. It was not possible to confirm this theory after the bioreactor investigation because the films were homogenized and sonicated to remove any residual bacteria biofilms. Additionally, the broth might have been salinized less than PBS. Catalytic ionic contact disrupts the sulfur-nitrogen bond, which is one of the primary mechanisms for boosting NO release from RSNOs. By day 28 as shown in the data, the release profile would be slower due to the decreased ion content.

In a 24-hour bacterial adhesion study conducted after sustained release of the SNAP-PDMS films for 125 days in PBS at 37 °C, the films were evaluated for their potential antibacterial properties. The films emitted around 0.1010 moles of NO per square meter per minute, but prior research indicated that even small doses of NO could be antibacterial. Even at very low NO fluxes from exogenous NO donating sources, the SNAP-PDMS film was able to reduce Staphylococcus aureus adhesion by 58.6%, suggesting that even very low NO fluxes from exogenous NO donating sources can have antibacterial properties.

Cytotoxicity of SNAP-PDMS

Any materials with potential leachates will affect the cells around them, thus it's critical to investigate any dangerous impacts. Using a standard technique, cytotoxic leachates from SNAP-PDMS films were tested on Cells cultured from mouse fibroblasts. To allow any leachates from the SNAP-PDMS films to dissolve into the DMEM, the films were submerged in amber vials for 24 hours at 37 °C. A 24-hour incubation period was followed by an exposure to leachates after the parallel-grown fibroblast cells had been exposed for 24 hours. CCK-8 kit-based cytotoxicity assays showed that more than 96 percent of the fibroblasts were alive when exposed to leachates from SNAP-PDMS films. SNAP-PDMS films appear to be biocompatible with mouse fibroblast cells based on the cytotoxicity study. Past experiments have shown that NO-releasing chemicals inhibit bacterial growth and activate platelets particularly effectively. It may be advantageous for the development of biomedical devices to have a high level of antibacterial activity, but this function should not be at the expense of harmful side effects on host mammalian cells. The use of antibacterial substances such as antibiotics, silver nanoparticles, or NO donors at extraordinarily high doses has been studied by other studies but there has been no safe therapeutic dose determined for mammalian cells. Therefore, the following research is critical in showing that NO-releasing PDMS films are antibacterial and antithrombotic without causing cytotoxicity. Moreover, at the end of the study, the morphology of the mouse fibroblast cells remained unchanged, showing that the cellular metabolism remained unchanged.

Because NAP, the forerunner of SNAP, is FDA-approved and widely used to treat heavy metal poisoning, this result was expected.57–58 NAP-based therapies have also been used to treat cystinuria for up to 155 days at doses as high as 2–4 g/day. 59 Various NO-releasing polymeric composites have previously been shown to have greater than 90% cell viability. 60–62 More animal research would be desirable in order to produce in vivo proof that would reinforce the efficacy of these drugs in preclinical settings.

Hemocompatibility of Extracorporeal Circuits SNAP-PDMS

Thrombus formation and platelet count were the primary variables examined in this study. SNAP-PDMS coatings were demonstrated to release NO to improve hemocompatibility of blood-contacting devices through examination of these properties. An hourly platelet count was taken during ECC testing, and the results were

compared to a baseline baseline taken before the experiment and corrected for hemodilution. It has been demonstrated that SNAP-PDMS releases for quite some time, but despite that, it still lacks development time, this study will just look at the first four hours of hemocompatibility to illustrate its early usefulness in an extracorporeal setting.

Platelet levels in all NO releasing circuits were at 75% of baseline after 4 hours, with flow around the initial flow through the ECC loop (100 mL min1). Prior to SNAP co-infusion with PDMS tubing, the baseline platelet count for control samples dropped to 12 percent after 4 hours, whereas NO-releasing tubing maintained a 62 percent count. As a result of a large flux of NO that was maintained throughout the trial, the SNAP-PDMS coating outperformed this strategy of introducing SNAP. Comparing pure silicone rubber to the PDMS control coating, the study found that it preserved a greater quantity of platelet count. Both the hydroxy-terminated PDMS and the aminosilanecrosslinker used have previously been shown to have hemocompatible properties, which can be attributed to this phenomenon.

Researchers were able to monitor thrombus growth by cutting up the ECC's thrombogenicity chamber and removing any visible clots. During the investigation, the control loops experienced significant clotting, resulting in the formation of a thick, dense layer of loosely bound thrombus that covered the chamber.

Conclusion

An effective long-term (> 4 months) NO releasing material was found to be the covalent attach of SNAP to PDMS in the present study. Prolonged and passive NO release minimized the risk that undesirable NO donors would seep into the surrounding environment, making it the ideal antibacterial and antithrombotic surface for long-term use. It was also noncytotoxic to mammals. Due to its covalent bond, the RSNO does not leach into the environment unlike the traditional method of incorporation. This is the key to its long-term stability and noncytotoxic properties. After a month of continuous exposure in a CDC bioreactor, the SNAP-PDMS material was still able to inhibit Staphylococcus aureus bacterial adhesion. As long as the films were released physiologically after 125 days, approximately 60% of all bacterial adhesion was blocked, suggesting that their antibacterial efficacy was retained even with low levels of sustained NO release.

REFERENCES

1. Gorbet MB; Sefton MV, Biomaterial-Associated Thrombosis: Roles of Coagulation Factors, Complement, Platelets and Leukocytes. *Biomaterials* 2004, 25 (26), 5681–5703.
2. Wu H; Moser C; Wang H-Z; Høiby N; Song Z-J, Strategies for Combating Bacterial Biofilm Infections. International journal of oral science 2015, 7 (1), 1–7.
3. MacMicking J; Xie; Nathan C, Nitric Oxide and Macrophage Function. *Annu. Rev. Immunol* 1997, 15 (1), 323–350.
4. Ignarro LJ; Buga GM; Wood KS; Byrns RE; Chaudhuri G, Endothelium-Derived Relaxing Factor Produced and Released from Artery and Vein Is Nitric Oxide. Proceedings of the National Academy of Sciences 1987, 84 (24), 9265–9269.
5. Frost MC; Reynolds MM; Meyerhoff ME, Polymers Incorporating Nitric Oxide Releasing/Generating Substances for Improved Biocompatibility of Blood-Contacting Medical Devices. Biomaterials 2005, 26 (14), 1685–1693.
6. Joslin JM; Lantvit SM; Reynolds MM, Nitric Oxide Releasing Tygon Materials: Studies in Donor Leaching and Localized Nitric Oxide Release at a Polymer-Buffer Interface. ACS Appl. Mater. Interfaces 2013, 5 (19), 9285–9294.
7. Bohl Masters KS; Lipke EA; Rice EE; Liel MS; Myler HA; Zygourakis C; Tulis DA; West JL, Nitric Oxide-Generating Hydrogels Inhibit Neointima Formation. J. Biomater. Sci. Polym. Ed 2005, 16 (5), 659–672.
8. Hrabie JA; Keefer LK, Chemistry of the Nitric Oxide-Releasing Diazeniumdiolate ("Nitrosohydroxylamine") Functional Group and Its Oxygen-Substituted Derivatives. Chem. Rev 2002, 102 (4), 1135–1154.
9. Annich GM; Meinhardt JP; Mowery KA; Ashton BA; Merz SI; Hirschl RB; Meyerhoff ME; Bartlett RH, Reduced Platelet Activation and Thrombosis in Extracorporeal Circuits Coated with Nitric Oxide Release Polymers. Crit. Care Med 2000, 28 (4), 915–920.
10. Handa H; Major TC; Brisbois EJ; Amoako KA; Meyerhoff ME; Bartlett RH, Hemocompatibility Comparison of Biomedical Grade Polymers Using Rabbit Thrombogenicity Model for Preparing Nonthrombogenic Nitric Oxide Releasing Surfaces. Journal of Materials Chemistry B 2014, 2 (8), 1059–1067.
11. Major TC; Brisbois EJ; Jones AM; Zanetti ME; Annich GM; Bartlett RH; Handa H, The Effect of a Polyurethane Coating Incorporating Both a Thrombin Inhibitor and Nitric Oxide on Hemocompatibility in Extracorporeal Circulation. Biomaterials 2014, 35 (26), 7271–7285.

12. Amoako KA; Archangeli C; Handa H; Major T; Meyerhoff ME; Annich GM; Bartlett RH, Thromboresistance Characterization of Extruded Nitric Oxide-Releasing Silicone Catheters. ASAIO journal (American Society for Artificial Internal Organs: 1992) 2012, 58 (3), 238.
13. Ren H; Coughlin MA; Major TC; Aiello S; Rojas Pena A; Bartlett RH; Meyerhoff ME, Improved in Vivo Performance of Amperometric Oxygen (P O2) Sensing Catheters Via Electrochemical Nitric Oxide Generation/Release. Anal. Chem 2015, 87 (16), 8067–8072.
14. Brisbois EJ; Major TC; Goudie MJ; Meyerhoff ME; Bartlett RH; Handa H, Attenuation of Thrombosis and Bacterial Infection Using Dual Function Nitric Oxide Releasing Central Venous Catheters in a 9day Rabbit Model. ActaBiomater. 2016, 44, 304–312.
15. Warkentin TE, Heparin-Induced Thrombocytopenia. Critical Decisions in Thrombosis and Haemostasis. BC Decker Inc. Hamilton,.Pagg 1998, 100–108. [Google Scholar]
16. Fidlar E; Jaques L, The Effect of Commercial Heparin on the Platelet Count. The Journal of laboratory and clinical medicine 1948, 33 (11), 1410–1423.
17. Monteiro DR; Gorup LF; Takamiya AS; Ruvollo-Filho AC; de Camargo ER; Barbosa DB, The Growing Importance of Materials That Prevent Microbial Adhesion: Antimicrobial Effect of Medical Devices Containing Silver. Int. J. Antimicrob. Agents 2009, 34 (2), 103–110.
18. Maneerung T; Tokura S; Rujiravanit R, Impregnation of Silver Nanoparticles into Bacterial Cellulose for Antimicrobial Wound Dressing. Carbohydr. Polym 2008, 72 (1), 43–51.
19. Kim JS; Kuk E; Yu KN; Kim J-H; Park SJ; Lee HJ; Kim SH; Park YK; Park YH; Hwang C-Y, Antimicrobial Effects of Silver Nanoparticles. Nanomed. Nanotechnol. Biol. Med 2007, 3 (1), 95–101.
20. Ruparelia JP; Chatterjee AK; Duttagupta SP; Mukherji S, Strain Specificity in Antimicrobial Activity of Silver and Copper Nanoparticles. ActaBiomater. 2008, 4 (3), 707–716.
21. Ramyadevi J; Jeyasubramanian K; Marikani A; Rajakumar G; Rahuman AA, Synthesis and Antimicrobial Activity of Copper Nanoparticles. Mater. Lett 2012, 71, 114–116.
22. Bagchi B; Dey S; Bhandary S; Das S; Bhattacharya A; Basu R; Nandy P, Antimicrobial Efficacy and Biocompatibility Study of Copper Nanoparticle Adsorbed Mullite Aggregates. Materials Science and Engineering: C 2012, 32 (7), 1897–1905.
23. Stigter M; Bezemer J; De Groot K; Layrolle P, Incorporation of Different Antibiotics into Carbonated Hydroxyapatite Coatings on Titanium Implants, Release and Antibiotic Efficacy. J. Controlled Release 2004, 99 (1), 127–137.
24. Mader JT; Calhoun J; Cobos J, In Vitro Evaluation of Antibiotic Diffusion from Antibiotic-Impregnated Biodegradable Beads and Polymethylmethacrylate Beads. Antimicrob. Agents Chemother 1997, 41 (2), 415–418.
25. Ungaro F; d'Angelo I; Coletta C; di Villa Bianca R.d. E.; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F, Dry Powders Based on Plga Nanoparticles for Pulmonary Delivery of Antibiotics: Modulation of Encapsulation Efficiency, Release Rate and Lung Deposition Pattern by Hydrophilic Polymers. J. Controlled Release 2012, 157 (1), 149–159.
26. Fischbach MA; Walsh CT, Antibiotics for Emerging Pathogens. Science 2009, 325 (5944), 1089–1093.
27. Taubes G, The Bacteria Fight Back. Science 2008, 321 (5887), 356–361.
28. Stewart PS; Costerton JW, Antibiotic Resistance of Bacteria in Biofilms. The lancet 2001, 358 (9276), 135–138.
29. Brisbois EJ; Major TC; Goudie MJ; Bartlett RH; Meyerhoff ME; Handa H, Improved Hemocompatibility of Silicone Rubber Extracorporeal Tubing Via Solvent Swelling-Impregnation of S-Nitroso-N-Acetylpenicillamine (Snap) and Evaluation in Rabbit Thrombogenicity Model. ActaBiomater. 2016, 37, 111–119.
30. Lu Y; Slomberg DL; Schoenfisch MH, Nitric Oxide-Releasing Chitosan Oligosaccharides as Antibacterial Agents. Biomaterials 2014, 35 (5), 1716–1724.
31. Lutzke A; Pegalajar-Jurado A; Neufeld BH; Reynolds MM, Nitric Oxide-Releasing S-Nitrosated Derivatives of Chitin and Chitosan for Biomedical Applications. Journal of Materials Chemistry B 2014, 2 (42), 7449–7458.
32. Pant J; Goudie MJ; Hopkins SP; Brisbois EJ; Handa H, Tunable Nitric Oxide Release from S-Nitroso-N-AcetylpenicillamineVia Catalytic Copper Nanoparticles for Biomedical Applications. ACS Appl. Mater. Interfaces
33. Hetrick EM; Schoenfisch MH, Antibacterial Nitric Oxide-Releasing Xerogels: Cell Viability and Parallel Plate Flow Cell Adhesion Studies. Biomaterials 2007, 28 (11), 1948–1956.
34. Barraud N; Hassett DJ; Hwang S-H; Rice SA; Kjelleberg S; Webb JS, Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas Aeruginosa. J. Bacteriol 2006, 188 (21), 7344–7353.
35. Hetrick EM; Shin JH; Paul HS; Schoenfisch MH, Anti-Biofilm Efficacy of Nitric Oxide-Releasing Silica Nanoparticles. Biomaterials 2009, 30 (14), 2782–2789.

36. Stasko NA; Fischer TH; Schoenfisch MH, S-Nitrosothiol-Modified Dendrimers as Nitric Oxide Delivery Vehicles. Biomacromolecules 2008, 9 (3), 834–841.
37. Lu Y; Slomberg DL; Shah A; Schoenfisch MH, Nitric Oxide-Releasing Amphiphilic Poly (Amidoamine)(Pamam) Dendrimers as Antibacterial Agents. Biomacromolecules 2013, 14 (10), 3589–3598.
38. He W; Frost MC, Direct Measurement of Actual Levels of Nitric Oxide (No) in Cell Culture Conditions Using Soluble No Donors. Redox biology 2016, 9, 1–14.
39. He W; Frost MC, Cellno Trap: Novel Device for Quantitative, Real-Time, Direct Measurement of Nitric Oxide from Cultured Raw 267.4 Macrophages. Redox biology 2016, 8, 383–397.
40. Moynihan HA; Roberts SM, Preparation of Some Novel S-Nitroso Compounds as Potential Slow-Release Agents of Nitric Oxide in Vivo. J. Chem. Soc., Perkin Trans. 1 1994, (7), 797–805.
41. Gierke GE; Nielsen M; Frost MC, S-Nitroso-N-Acetyl-D-Penicillamine Covalently Linked to Polydimethylsiloxane (Snap–Pdms) for Use as a Controlled Photoinitiated Nitric Oxide Release Polymer. Science and technology of advanced materials 2011, 12 (5), 055007.
42. Williams DLH, The Chemistry of S-Nitrosothiols. Acc. Chem. Res 1999, 32 (10), 869–876.
43. Bartberger MD; Houk K; Powell SC; Mannion JD; Lo KY; Stamler JS; Toone EJ, Theory, Spectroscopy, and Crystallographic Analysis of S-Nitrosothiols: Conformational Distribution Dictates Spectroscopic Behavior. J. Am. Chem. Soc 2000, 122 (24), 5889–5890.
44. Pant J; Goudie MJ; Hopkins SP; Brisbois EJ; Handa H, Tunable Nitric Oxide Release from S-Nitroso-N-AcetylpenicillamineVia Catalytic Copper Nanoparticles for Biomedical Applications. ACS Appl. Mater. Interfaces 2017, 9 (18), 15254–15264.
45. Brisbois EJ; Handa H; Major TC; Bartlett RH; Meyerhoff ME, Long-Term Nitric Oxide Release and Elevated Temperature Stability with S-Nitroso-N-Acetylpenicillamine (Snap)-Doped Elast-Eon E2as Polymer. Biomaterials 2013, 34 (28), 6957–6966.
46. Handa H; Brisbois EJ; Major TC; Refahiyat L; Amoako KA; Annich GM; Bartlett RH; Meyerhoff ME, In Vitro and in Vivo Study of Sustained Nitric Oxide Release Coating Using Diazeniumdiolate-Doped Poly (Vinyl Chloride) Matrix with Poly (Lactide-Co-Glycolide) Additive. Journal of Materials Chemistry B 2013, 1 (29), 3578–3587.
47. Major TC; Brant DO; Reynolds MM; Bartlett RH; Meyerhoff ME; Handa H; Annich GM, The Attenuation of Platelet and Monocyte Activation in a Rabbit Model of Extracorporeal Circulation by a Nitric Oxide Releasing Polymer. Biomaterials 2010, 31 (10), 2736–2745.
48. Lu Y; Shah A; Hunter RA; Soto RJ; Schoenfisch MH, S-Nitrosothiol-Modified Nitric Oxide-Releasing Chitosan Oligosaccharides as Antibacterial Agents. ActaBiomater. 2015, 12, 62–69.
49. Nablo BJ; Rothrock AR; Schoenfisch MH, Nitric Oxide-Releasing Sol–Gels as Antibacterial Coatings for Orthopedic Implants. Biomaterials 2005, 26 (8), 917–924.
50. Pant J; Gao J; Goudie MJ; Hopkins S; Locklin J; Handa H, A Multi-Defense Strategy: Enhancing Bactericidal Activity of a Medical Grade Polymer with a Nitric Oxide Donor and Surface-Immobilized Quaternary Ammonium Compound. ActaBiomater. 2017.
51. Colletta A; Wu J; Wo Y; Kappler M; Chen H; Xi C; Meyerhoff ME, S-Nitroso-N-Acetylpenicillamine (Snap) Impregnated Silicone Foley Catheters: A Potential Biomaterial/Device to Prevent Catheter-Associated Urinary Tract Infections. ACS biomaterials science & engineering 2015, 1 (6), 416–424.
52. Williams DL; Bloebaum RD, Observing the Biofilm Matrix of Staphylococcus EpidermidisAtcc 35984 Grown Using the Cdc Biofilm Reactor. Microsc. Microanal 2010, 16 (02), 143–152.
53. Sundaram J; Pant J; Goudie MJ; Mani S; Handa H, Antimicrobial and Physicochemical Characterization of Biodegradable, Nitric Oxide-Releasing Nanocellulose–Chitosan Packaging Membranes. J. Agric. Food Chem 2016, 64 (25), 5260–5266.
54. Xu L-C; Wo Y; Meyerhoff ME; Siedlecki CA, Inhibition of Bacterial Adhesion and Biofilm Formation by Dual Functional Textured and Nitric Oxide Releasing Surfaces. ActaBiomater. 2017.
55. Hetrick EM; Schoenfisch MH, Reducing Implant-Related Infections: Active Release Strategies. Chem. Soc. Rev 2006, 35 (9), 780–789.
56. AshaRani P; Low KahMun G; Hande MP; Valiyaveettil S, Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells. ACS nano 2008, 3 (2), 279–290.
57. Kark RP; Poskanzer DC; Bullock JD; Boylen G, Mercury Poisoning and Its Treatment with N-Acetyl-D, L-Penicillamine. New Engl. J. Med 1971, 285 (1), 10–16.
58. Stephens A; Watts R, The Treatment of Cystinuria with N-Acetyl-D-Penicillamine, a Comparison with the Results of D-Penicillamine Treatment. QJM 1971, 40 (3), 355–370.

59. Stokes G; Potts J; Lotz M; Bartter F, New Agent in the Treatment of Cystinuria: N-Acetyl-D-Penicillamine. Br. Med. J 1968, 1 (5587), 284.
60. Hetrick EM; Shin JH; Stasko NA; Johnson CB; Wespe DA; Holmuhamedov E; Schoenfisch MH, Bactericidal Efficacy of Nitric Oxide-Releasing Silica Nanoparticles. Acs Nano 2008, 2 (2), 235–246.
61. Masters KSB; Leibovich SJ; Belem P; West JL; Poole-Warren LA, Effects of Nitric Oxide Releasing Poly (Vinyl Alcohol) Hydrogel Dressings on Dermal Wound Healing in Diabetic Mice. Wound Repair Regen. 2002, 10 (5), 286–294.
62. Coneski PN; Rao KS; Schoenfisch MH, Degradable Nitric Oxide-Releasing Biomaterials Via Post-Polymerization Functionalization of Cross-Linked Polyesters. Biomacromolecules 2010, 11 (11), 3208–3215.
63. Zhu R; Wang X; Yang J; Wang Y; Zhang Z; Hou Y; Lin F, Influence of Hydroxyl-Terminated Polydimethylsiloxane on High-Strength Biocompatible Polycarbonate Urethane Films. Biomedical Materials 2016, 12 (1), 015011.
64. Marxer SM; Schoenfisch MH, Sol− Gel Derived Potentiometric Ph Sensors. Anal. Chem 2005, 77 (3), 848–853.

Cite this article:
Dr. ParijaJyothiPrakash. Snap (S-Nitroso-N-Acetyl Penicillamine) Has Long-Term Biocompatibility Through Covalent Immobilization And Exhibits Sustained Nitric Oxide Release For 4 Months.ActaBiomedicaScientia, *2019; 6(2):171-180*.